PureTech Health PLC
PRTC16.790USD
+0.040+0.24%
Market hours （ET）Quotes delayed by 15 min
4.03BMarket Cap
93.63P/E TTM
More Details of PureTech Health PLC Company
PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.
PureTech Health PLC Info
Ticker SymbolPRTC
Company namePureTech Health PLC
IPO dateJun 19, 2015
CEOLyne (Robert)
Number of employees56
Security typeDepository Receipt
Fiscal year-endJun 19
Address6 Tide Street
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02210
Phone16174822333
Websitehttps://puretechhealth.com/
Ticker SymbolPRTC
IPO dateJun 19, 2015
CEOLyne (Robert)
Company Executives of PureTech Health PLC
Name
Name/Position
Position
Shareholding
Change
Ms. Kiran Mazumdar-Shaw
Ms. Kiran Mazumdar-Shaw
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sharon Barber-lui
Ms. Sharon Barber-lui
Interim Independent Non-Executive Chairman of the Board
Interim Independent Non-Executive Chairman of the Board
--
--
Dr. Michele A. M. Holcomb, Ph.D.
Dr. Michele A. M. Holcomb, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Langer (Robert S Jr)
Langer (Robert S Jr)
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Eric Elenko, Ph.D.
Dr. Eric Elenko, Ph.D.
President, Director
President, Director
--
--
Mr. Robert (Rob) Lyne
Mr. Robert (Rob) Lyne
Interim Chief Executive Officer
Interim Chief Executive Officer
--
--
Dr. Charles H. Sherwood, Ph.D.
Dr. Charles H. Sherwood, Ph.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
--
--
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Kiran Mazumdar-Shaw
Ms. Kiran Mazumdar-Shaw
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sharon Barber-lui
Ms. Sharon Barber-lui
Interim Independent Non-Executive Chairman of the Board
Interim Independent Non-Executive Chairman of the Board
--
--
Dr. Michele A. M. Holcomb, Ph.D.
Dr. Michele A. M. Holcomb, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Langer (Robert S Jr)
Langer (Robert S Jr)
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Eric Elenko, Ph.D.
Dr. Eric Elenko, Ph.D.
President, Director
President, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 9
Updated: Sun, Nov 9
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Pentwater Capital Management LP
0.31%
Millennium Management LLC
0.07%
Diadema Partners LP
0.03%
Other
99.59%
Shareholders
Shareholders
Proportion
Pentwater Capital Management LP
0.31%
Millennium Management LLC
0.07%
Diadema Partners LP
0.03%
Other
99.59%
Shareholder Types
Shareholders
Proportion
Hedge Fund
0.42%
Other
99.58%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
20
111.77K
0.46%
-247.60K
2025Q2
15
335.52K
1.39%
-63.86K
2025Q1
14
393.56K
1.64%
-4.75K
2024Q4
14
374.87K
1.56%
+317.90K
2024Q3
13
30.04K
0.13%
-317.21K
2024Q2
12
323.23K
1.35%
+280.87K
2024Q1
9
25.15K
0.09%
-3.71K
2023Q4
10
11.40K
0.04%
-82.93K
2023Q3
12
84.27K
0.31%
-16.31K
2023Q2
11
83.51K
0.30%
-16.43K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Pentwater Capital Management LP
50.00K
0.21%
+16.44K
+48.99%
Jun 30, 2025
Millennium Management LLC
23.86K
0.1%
-21.05K
-46.88%
Jun 30, 2025
Diadema Partners LP
7.32K
0.03%
+7.32K
--
Jun 30, 2025
Persistent Asset Partners Limited
1.69K
0.01%
+1.69K
--
Jun 30, 2025
Geode Capital Management, L.L.C.
770.00
0%
--
--
Aug 31, 2025
Dimensional Fund Advisors, L.P.
316.00
0%
--
--
May 31, 2025
UBS Financial Services, Inc.
20.00
0%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
1.28K
0.01%
--
--
Aug 31, 2025
Atlantic Union Bankshares Corporation
115.00
0%
+115.00
--
Jun 30, 2025
Portolan Capital Management, L.L.C.
27.80K
0.12%
+15.91K
+133.87%
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of PureTech Health PLC?
The top five shareholders of PureTech Health PLC are:
Pentwater Capital Management LP holds 50.00K shares, accounting for 0.21% of the total shares.
Millennium Management LLC holds 23.86K shares, accounting for 0.10% of the total shares.
Diadema Partners LP holds 7.32K shares, accounting for 0.03% of the total shares.
Persistent Asset Partners Limited holds 1.69K shares, accounting for 0.01% of the total shares.
Geode Capital Management, L.L.C. holds 770.00 shares, accounting for 0.00% of the total shares.
Pentwater Capital Management LP holds 50.00K shares, accounting for 0.21% of the total shares.
Millennium Management LLC holds 23.86K shares, accounting for 0.10% of the total shares.
Diadema Partners LP holds 7.32K shares, accounting for 0.03% of the total shares.
Persistent Asset Partners Limited holds 1.69K shares, accounting for 0.01% of the total shares.
Geode Capital Management, L.L.C. holds 770.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of PureTech Health PLC?
The top three shareholder types of PureTech Health PLC are:
Pentwater Capital Management LP
Millennium Management LLC
Diadema Partners LP
Pentwater Capital Management LP
Millennium Management LLC
Diadema Partners LP
How many institutions hold shares of PureTech Health PLC (PRTC)?
As of 2025Q3, 20 institutions hold shares of PureTech Health PLC, with a combined market value of approximately 111.77K, accounting for 0.46% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -0.93%.
What is the biggest source of revenue for PureTech Health PLC?
In --, the -- business generated the highest revenue for PureTech Health PLC, amounting to -- and accounting for --% of total revenue.
